Andrew Dudum, co-founder and CEO of Hims & Hers Health, pushed back against the Federal Trade Commission’s lawsuit against the telehealth company, arguing that the case does not accurately reflect how Hims & Hers operates. The comments came as the company faces regulatory scrutiny over customer privacy and billing practices while simultaneously reshaping its business around branded GLP-1 treatments and artificial intelligence.
The FTC filed its lawsuit against Hims & Hers on July 29, 2026, together with the Utah Division of Consumer Protection and Los Angeles County. The agency alleges that the company shared sensitive customer health information with advertising platforms and engaged in deceptive subscription and billing practices. Hims & Hers has rejected the allegations and said it intends to defend itself.
Andrew Dudum challenges the FTC’s portrayal of Hims & Hers
The central issue in Andrew Dudum’s response is the gap between the FTC’s allegations and the company’s description of its healthcare platform.
According to the FTC’s lawsuit, Hims & Hers allegedly shared certain customer information with third-party advertising companies, including Meta and Snap, while presenting privacy protections to consumers. The agency also alleges that customers could be charged for prescriptions before completing a consultation and that cancellation procedures were unnecessarily difficult.
Hims & Hers has disputed those claims. The company previously said the FTC had disregarded evidence supplied during its investigation and characterized the action as an effort to generate headlines rather than legitimate consumer-protection enforcement.
The dispute follows an FTC investigation that began in 2023. Company filings say the commission issued a Civil Investigative Demand seeking information about privacy, advertising, subscription and cancellation practices. Settlement discussions ultimately failed before the lawsuit was filed in federal court.
GLP-1s remain a major part of the legal backdrop
The Andrew Dudum story is also closely connected to Hims & Hers’ rapid expansion into GLP-1 weight-loss treatments.
The company began offering compounded injectable semaglutide in 2024 as part of its weight-loss business. Its filings later identified regulatory restrictions, supply issues and changing federal policy around compounded GLP-1 medications as significant factors affecting the business.
Hims & Hers subsequently moved away from compounded GLP-1 products and toward FDA-approved branded treatments following legal and regulatory pressure. The company reached a deal with Novo Nordisk earlier in 2026 that allowed Hims & Hers to sell branded Wegovy and Ozempic while withdrawing the related patent lawsuit, with Novo reserving the right to refile in the event of a breach.
That transition has become an important part of the company’s broader strategy. During its second-quarter earnings period, Hims & Hers reported higher revenue guidance while also facing significant costs associated with litigation and restructuring.
AI is becoming another pillar of Dudum’s strategy
While the FTC dispute creates legal pressure, Andrew Dudum is also positioning Hims & Hers around artificial intelligence and personalized healthcare.
Hims & Hers introduced an AI-native care experience for Hers weight-loss members in August. The company described the system as a doctor-led experience designed to provide personalized guidance and ongoing support based on a customer’s progress.
The company’s filings also describe artificial intelligence as part of its technology strategy, including tools that can assist providers and other parts of the healthcare experience. At the same time, Hims & Hers acknowledges that inaccurate or incomplete AI-generated information could create liability and reputational risks.
That makes AI more than a technology initiative for the company. It is becoming part of Hims & Hers’ attempt to build a more personalized digital healthcare model as its earlier growth around compounded GLP-1 medications comes under greater regulatory pressure.
What happens next for Hims & Hers
The FTC case remains unresolved. Hims & Hers said in its latest regulatory filing that the lawsuit seeks injunctive relief, monetary relief, civil penalties and other remedies, while the company maintains that it has strong arguments and plans to defend itself.
The company is also facing separate litigation connected to the same underlying allegations, including a putative class action filed in federal court. Hims & Hers has said it cannot currently predict the outcome or estimate a reasonably possible financial loss from that litigation.
For Andrew Dudum, the challenge is therefore broader than one lawsuit. Hims & Hers is simultaneously navigating consumer-protection scrutiny, the regulatory shift surrounding GLP-1 medications and a strategic push into AI-powered healthcare.
The company’s response to those pressures will help determine how successfully it can transition from its earlier compounded-drug growth model while defending the practices that helped build its digital health platform.
This news has been compiled using information gathered from various platforms and is intended for general informational purposes only.
